請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61026完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 郭柏秀(Po-Hsiu Kuo) | |
| dc.contributor.author | Shih-Jie Lin | en |
| dc.contributor.author | 林詩婕 | zh_TW |
| dc.date.accessioned | 2021-06-16T10:42:08Z | - |
| dc.date.available | 2018-09-24 | |
| dc.date.copyright | 2013-09-24 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-08-13 | |
| dc.identifier.citation | Annerbrink, K., Westberg, L., Olsson, M., Andersch, S., din, I. S., Holm, G. r., Allgulander, C., & Eriksson, E. (2011). Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. Psychiatric Genetics, 21(2), 85-89.
Arango, V., Underwood, M., Boldrini, M., Tamir, H., Kassir, S., Hsiung, S.-c., Chen, J., & Mann, J. (2001). Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology, 25(6), 892-903. Benca, R. M. (2005). Mood disorders. In Meir H. Kryger, Thomas Roth & a. W. C. Dement (Eds.), Principles and Practice of Sleep Medicine (4 ed.): Philadelphia: Elsevier Saunders. Boyd, J. H., & Weissman, M. M. (1981). Epidemiology of Affective Disorders A Reexamination and Future Directions. Archives of General Psychiatry, 38(9), 1039-1046. Brundin, L., Bjorkqvist, M., Petersen, A., & Traskman-Bendz, L. (2007). Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology, 17(9), 573–579. Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index (PSQI): A new instrument for psychiatric research and practice. Psychiatry Research, 28(2), 193–213. Cermakian, N., & Boivin, D. B. (2003). A molecular perspective of human circadian rhythm disorders. Brain Research Reviews, 42(3), 204-220. Chen, W., Ye, J., Han, D., Yin, G., Wang, B., & Zhang, Y. (2012). Association of prepro-orexin polymorphism with obstructive sleep apnea/hypopnea syndrome. American Journal of Otolaryngology, 33(1), 31-36. Chiara, G. D., Loddo, P., & Tanda, G. (1999). Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression. Biological Psychiatry, 46(12), 1624-1633. Davis, J. F., Choi, D. L., & Benoit, S. C. (2011). Orexigenic Hypothalamic Peptides Behavior and Feeding. In Victor R. Preedy, Ronald Ross Watson & C. R. Martin (Eds.), Handbook of Behavior, Food and Nutrition (pp. 355-369): Springer New York. Dawson, D., & Armstrong, S. M. (1996). Chronobiotics--Drugs that shift rhythms. Pharmacology & Therapeutics, 69(1), 15-36. Endicott, J., & Spitzer, R. L. (1978). A Diagnostic Interview The Schedule for Affective Disorders and Schizophrenia. Archives of General Psychiatry, 35(7), 837-844. Fava, M. (2004). Daytime sleepiness and insomnia as correlates of depression. Journal of Clinical Psychiatry, 65(suppl 16), 27-32. Feng, P., Vurbic, D., Wu, Z., Hu, Y., & Strohl, K. (2008). Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. Journal of Psychopharmacology, 22(7), 784-791. Ford, D. E., & Kamerow, D. B. (1989). Epidemiologic study of sleep disturbance and psychiatric disorders: an opportunity for prevention? Journal of the American Medical Association, 262, 1479-1484. Fukunaka, Y., Shinkai, T., Hwang, R., Hori, H., Utsunomiya, K., Sakata, S., Naoe, Y., Shimizu, K., Matsumoto, C., Ohmori, O., & Nakamura, J. (2007). The Orexin 1 Receptor (HCRTR1) Gene as a Susceptibility Gene Contributing to Polydipsia-Hyponatremia in Schizophrenia. NeuroMolecular Medicine, 9(4), 292-297. Gencik, M., Dahmen, N., Wieczorek, S., Kasten, M., Bierbrauer, J., Anghelescu, I., Szegedi, A., Saecker, A. M. M., & Epplen, J. T. (2001). A prepro-orexin gene polymorphism is associated with narcolepsy. Neurology, 56(1), 115-117. Hagan, J. J., Leslie, R. A., Patel, S., Evans, M. L., Wattam, T. A., Holmes, S., Benham, C. D., Taylor, S. G., Routledge, C., Hemmati, P., Munton, R. P., Ashmeade, T. E., Shah, A. S., Hatcher, J. P., Hatcher, P. D., Jones, D. N. C., Smith, M. I., Piper, D. C., Hunter, A. J., Porter, R. A., & Upton, N. (1999). Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proceedings of the National Academy of Sciences, 96(19), 10911–10916. Iovieno, N., Nieuwenhuizen, A. v., Clain, A., Baer, L., & Nierenberg, A. A. (2011). Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depression and Anxiety, 28(2), 137-144. Kastin, A. J., & Akerstrom, V. (1999). Orexin A but Not Orexin B Rapidly Enters Brain from Blood by Simple Diffusion. Journal of Pharmacology and Experimental Therapeutics, 289(1), 219-223. Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 62(6), 617-627. Kessler, R. C., & Ustun, T. B. (2004). The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). International Journal of Methods in Psychiatric Research, 13(2), 93-121. Ko, H.-C., Huang, K.-Y., Lee, Y.-D., & Chuang, L.-C. (1996). Beck Depression Inventory as a Screening Tool for Pre- and Postpartum Depression among Chinese Women. Chinese Journal of Public Health, 15(3), 208-219. Kunz, D. (2004). Chronobiotic protocol and circadian sleep propensity index: New tools for clinical routine and research on melatonin and sleep. Pharmacopsychiatry, 37(4), 139-146. Langmead, C. J., Jerman, J. C., Brough, S. J., Scott, C., Porter, R. A., & Herdon, H. J. (2004). Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. British Journal of Pharmacology, 141(2), 340-346. Lecea, L. D., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., Frankel, W. N., Pol, A. N. v. d., Bloom, F. E., Gautvik, K. M., & Sutcliffe, J. G. (1998). The hypocretins: Hypothalamus-specific peptides with neuroexcitatoryactivity. Proceedings of the National Academy of Sciences, 95(1), 322-327. Lu, M.-L., Che, H.-H., Chang, S.-W., & Shen, W. W. (2002). Reliability and Validity of the Chinese Version of the Beck Depression Inventory-II (中文版貝克憂鬱量表第二版之信度和效度). Taiwanese Journal of Psychiatry, 16(4), 301∼310. Matthews, P. R., & Harrison, P. J. (2012). A morphometric, immunohistochemical, and in situ hybridization study of the dorsal raphe nucleus in major depression, bipolar disorder, schizophrenia, and suicide. Journal of Affective Disorders, 137(1-3), 125-134. McClintock, S. M., Husain, M. M., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Trivedi, M. H., Cook, I., Morris, D., Warden, D., & Rush, A. J. (2011). Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. Journal of Clinical Psychopharmacology, 31(2), 180-186. Meerabux, J., Iwayama, Y., Sakurai, T., Ohba, H., Toyota, T., Yamada, K., Nagata, R., Irukayama-Tomobe, Y., Shimizu, H., Yoshitsugu, K., Ohta, K., & Yoshikawa, T. (2005). Association of An Orexin 1 Receptor 408Val Variant with Polydipsia–Hyponatremia in Schizophrenic Subjects. Biological Psychiatry, 58(5), 401-407. Mendlewicz, J. (2009). Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders. World Journal of Biological Psychiatry, 10(4), 269-275. Merck. (2010). Results Presented from Phase IIb Clinical Study of Merck's Investigational Insomnia Therapy MK-4305. from http://www.drugs.com/clinical_trials/results-presented-phase-iib-clinical-study-merck-s-investigational-insomnia-therapy-mk-4305-9566.html Mieda, M., Willie, J. T., Hara, J., Sinton, C. M., Sakurai, T., & Yanagisawa, M. (2004). Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proceedings of the National Academy of Sciences, 101(13), 4649–4654. Monti, J. M., Alvarin˜o, F., Cardinali, D., Savio, I., & Pintos, A. (1999). Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Archives of Gerontology and Geriatrics, 28(2), 85-98. Morairty, S. R., Revel, F. G., Malherbe, P., Moreau, J.-L., Valladao, D., Wettstein, J. G., Kilduff, T. S., & Borroni, E. (2012). Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone. PLoS ONE, 7(7), e39131. Muraki, Y., Yamanaka, A., Tsujino, N., Kilduff, T. S., Goto, K., & Sakurai, T. (2004). Serotonergic Regulation of the Orexin/Hypocretin Neurons through the 5-HT1A Receptor. Journal of Neuroscience, 24(32), 7159 -7166. Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychological Medicine, 40(1), 41-50. Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington III, J. J., Rosenbaum, J. R., & Fava, M. (1999). Residual symptoms in depressed patients who respond acutely to fluoxetine. Journal of Clinical Psychiatry, 60(4), 221-225. Nutt, D. J. (2008). Relationship of neurotransmitters to the symptoms of major depressive disorder. Journal of Clinical Psychiatry, 69(Suppl E1), 4-7. Ohno, K., & Sakurai, T. (2008). Orexin neuronal circuitry: Role in the regulation of sleep and wakefulness. Frontiers in Neuroendocrinology, 29(1), 70-87. Peyron, C., Tighe, D. K., Pol, A. N. v. d., Lecea, L. d., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. Journal of Neuroscience, 18(23), 9996–10015. Pigeon, W. R., Hegel, M., Unutzer, J., Fan, M.-Y., Sateia, M. J., Lyness, J. M., Phillips, C., & Perlis, M. L. (2008). Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort ? Sleep, 31(4), 481-488. Piper, D. C., Upton, N., Smith, M. I., & Hunter, A. J. (2000). The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. European Journal of Neuroscience, 12(2), 726-730. Porstmann, T., & Kiessig, S. (1992). Enzyme immunoassay techniques. An overview. Journal of Immunological Methods, 150(1-2), 5-21. Preacher, K. J., & Hayes, A. F. (2004). SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behavior Research Methods, Instruments, & Computers, 36(4), 717-731. Rainero, I., Ostacoli, L., Rubino, E., Gallone, S., Picco, L. R., Fenoglio, P., Negro, E., Rosso, C., Martino, P. D., Marchi, M. D., Furlan, P. M., & Pinessi, L. (2011). Association between Major Mood Disorders and the hypocretin receptor 1 gene. Journal of Affective Disorders, 130(3), 487-491. Rainero, I., Rubino, E., Valfre, W., Gallone, S., Martino, P. D., Zampella, E., & Pinessi, L. (2007). Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. Journal of Headache and Pain, 8(3), 152-156. Reghunandanan, V., & Reghunandanan, R. (2006). Neurotransmitters of the suprachiasmatic nuclei. [review]. Journal of Circadian Rhythms, 4(2). Rissling, I., Korner, Y., Geller, F., Stiasny-Kolster, K., Oertel, W. H., & Moller, J. C. (2005). Preprohypocretin polymorphisms in Parkinson disease patients reporting 'sleep attacks'. Sleep, 28(7), 871-875. Sabate, E. (2004). Priority Medicines for Europe and the World 'A Public Health Approach to Innovation'. In W. H. Organization (Ed.), Depression in Young People and the Elderly: World Health Organization. Sakurai, T. (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Neuroscience, 8(3), 171-181. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R. S., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W.-S., Terrett, J. A., Elshourbagy, N. A., Bergsma, D. J., & Yanagisawa, M. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 92(4), 573-585. Salomon, R. M., Ripley, B., Kennedy, J. S., Johnson, B., Schmidt, D., Zeitzer, J. M., Nishino, S., & Mignot, a. E. (2003). Diurnal Variation of Cerebrospinal Fluid Hypocretin-1 (Orexin-A) Levels in Control and Depressed Subjects. Society of Biological Psychiatry, 54(2), 96-104. Sasaki, K., Suzuki, M., Mieda, M., Tsujino, N., Roth, B., & Sakurai, T. (2011). Pharmacogenetic Modulation of Orexin Neurons Alters Sleep/Wakefulness States in Mice. PLoS ONE, 6(5), e20360. Scammell, T. E., & Winrow, C. J. (2011). Orexin Receptors: Pharmacology and Therapeutic Opportunities. The Annual Review of Pharmacology and Toxicology, 51, 243-266. Schmidt, F. M., Arendt, E., Steinmetzer, A., Bruegel, M., Kratzsch, J., Straus, M., Baum, P., Hegerl, U., & Schonknecht, P. (2011). CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Research, 190(2-3), 240-243. Schmidt, F. M., Brugel, M., Kratzsch, J., Straus, M., Sander, C., Baum, P., Thiery, J., Hegerl, U., & Schonknecht, P. (2010). Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neuroscience Letters, 483(1), 20-22. Scotta, M. M., Marcusb, J. N., Pettersenc, A., Birnbaumc, S. G., Mochizukid, T., Scammelld, T. E., Nestlere, E. J., Elmquista, J. K., & Lutterc, M. (2011). Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behavioural Brain Research, 222(2), 289-294. Srinivasan, V. (1997). Melatonin, biological rhythm disorders and phototherapy. Indian Journal of Physiology and Pharmacology, 41(4), 309-328. Srinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., Parry, B., & Cardinali, D. R. (2006). Melatonin in mood disorders. The World Journal of Biological Psychiatry, 7(3), 138-151. Stoppler, M. C. (2012). What is the relationship between insulin resistance and diabetes? Insulin Resistance, from http://www.medicinenet.com/insulin_resistance/article.htm Strawn, J. R., Pyne-Geithman, G. J., Ekhator, N. N., Horn, P. S., Uhde, T. W., Shutter, L. A., Baker, D. G., & Jr., T. D. G. (2010). Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology, 35(7), 1001-1007. Sunderajan, P., Gaynes, B. N., Wisniewski, S. R., Miyahara, S., Fava, M., Akingbala, F., DeVeaugh-Geiss, J., Rush, A. J., & Trivedi, M. H. (2010). Insomnia in patients with depression : a STAR* D report. CNS Spectrums, 15(6), 394-404. Thannickal, T. C., Moore, R. Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., Cornford, M., & Siegel, J. M. (2000). Reduced number of hypocretin neurons in human narcolepsy. Neuron, 27, 469-474. Tsuno, N., Besset, A., & Ritchie, K. (2005). Sleep and Depression. Journal of Clinical Psychiatry, 66(10), 1254-1269. Willie, J. T., Takahira, H., Shibahara, M., Hara, J., Nomiyama, M., Yanagisawa, M., & Sakurai, T. (2011). Ectopic Overexpression of Orexin Alters Sleep/Wakefulness States and Muscle Tone Regulation during REM Sleep in Mice. Journal of Molecular Neuroscience, 43(2), 155-161. Willyard, C. (2012). New class of sleep drugs may offer a safer night's rest. Nature Medicine, 18(7), 996. Winrow, C. J., Gotter, A. L., Cox, C. D., Doran, S. M., Tannenbaum, P. L., Breslin, M. J., Garson, S. L., Fox, S. V., Harrell, C. M., Stevens, J., Reiss, D. R., Cui, D., Coleman, P. J., & Renger, J. J. (2011). Promotion of Sleep by Suvorexant — A Novel Dual Orexin Receptor Antagonist. Journal of Neurogenetics, 25(1-2), 52-61. Winrow, C. J., Gotter, A. L., Cox, C. D., Tannenbaum, P. L., Garson, S. L., Doran, S. M., Breslin, M. J., Schreier, J. D., Fox, S. V., Harrell, C. M., Stevens, J., Reiss, D. R., Cui, D., Coleman, P. J., & Renger, J. J. (2012). Pharmacological characterization of MK-6096 - A dual orexin receptor antagonist for insomnia. Neuropharmacology, 62(2), 978-987. Winsky-Sommerer, R., Yamanaka, A., Diano, S., Borok, E., Roberts, A. J., Sakurai, T., Kilduff, T. S., Horvath, T. L., & Lecea, L. d. (2004). Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. Journal of Neuroscience, 24(50), 11439-11448. Yamanaka, A., Tsujino, N., Funahashi, H., Honda, K., Guan, J.-l., Wang, Q.-P., Tominaga, M., Goto, K., Shioda, S., & Sakurai, T. (2002). Orexins activate histaminergic neurons via the orexin 2 receptor. Biochemical and Biophysical Research Communications, 290(4), 1237-1245. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61026 | - |
| dc.description.abstract | 目的：近90％的重度憂鬱症（MDD）的患者都有睡眠障礙。此外，睡眠問題往往持續出現在緩解期。促醒激素（Orexin）是一種神經傳導分子又名食慾素（Hypocretin），會調節睡眠與清醒週期，並可能和MDD的神經病理學相關。目前的研究在探討促醒激素受體的基因變異、重鬱症和睡眠特徵的關聯。此外，一些過去針對檢測促醒激素濃度在異質性情緒相關疾病患者的腦脊液中表現的研究出現相互矛盾的結果。我們也另外評估了血漿中促醒激素濃度和睡眠品質及情緒狀態之間的關係。
方法：個案的收集是包含臨床診斷為重鬱症患者和健康對照組。匹茲堡睡眠質量指數（PSQI）用來衡量睡眠品質，切點大於5表示睡眠質量差。貝克憂鬱量表第二版（BDI-II）針對MDD患者症狀的嚴重程度來進行評估。我們在619名受試者針對兩個在促醒激素的兩個受體基因（HCRTR1, HCRTR2）上的單點核甘酸多型性（SNP; rs2271933、 rs2653349）進行基因分型中的檢測。在132位受試者的血漿測定促醒激素濃度採用ELISA kit。根據疾病狀態和睡眠品質，受試者被分成4個子群體。我們用Kruskal-Wallis檢定，來評估各子群體的促醒激素濃度。用回歸模型來檢定在同時調整性別和年齡後促醒激素受體的基因變異與促醒激素濃度，對於睡眠變量（如睡眠時間，睡眠效率，睡眠延遲，和失眠相關的變項）以及貝克憂鬱量表第二版分數的影響。 結果：促醒激素的單點核甘酸多型性在rs2271933（HCRTR1）顯示與PSQI總分（P = 0.006）有關連。個體帶有G等位基因會增加MDD的風險（OR= 1.48，P= 0.014）及日間功能較差（OR= 1.46，P =0.0124）。血漿促醒激素濃度在對照組且有良好的睡眠品質（中位數：0.67 ng/ml，P = 0.04）明顯高於其他子群（最低濃度是MDD且睡眠品質差：0.058 ng/ml）。促醒激素濃度較高對於發生睡眠潛伏期較長（OR= 0.39，P = 0.014）以及發生長的睡眠潛伏期頻率較高（OR= 0.36，P = 0.019）有保護作用。更高的睡眠效率是與較高的血漿促醒激素濃度（β= 2.48，P = 0.027）相關。同時，促醒激素濃度與BDI-II得分呈現負相關（β= -4.129，P = 0.016）。 結論：促醒激素受體上的基因變異與血漿促醒激素濃度對於睡眠相關的功能和情緒紊亂都有影響。越低的血漿促醒激素濃度與睡眠質量較差及更嚴重的憂鬱症狀有關係。 | zh_TW |
| dc.description.abstract | Objective: Nearly 90% of patients with Major depressive Disorder (MDD) report sleep disturbances. Additionally, sleep problems often persist in the remission period. Orexins are neuropeptides also named hypocretins that have known to regulate sleep-wakeful cycle and might be involved in the psychopathology of MDD. The current study aimed to examine associations of genetic variants in the orexin receptor genes with MDD and sleep features. Furthermore, few previous studies that examined orexin level in the cerebrospinal fluid of patients with heterogeneous mood related disorders exhibit conflicting results. We also evaluated the relationships between plasma orexin level and sleep quality and mood status.
Methods: We recruited clinical diagnosed MDD patients and healthy controls. Sleep quality was measured by Pittsburgh Sleep Quality Index (PSQI), with cut-off value 5 indicating poor sleep quality. Beck Depression Inventory II (BDI-II) was assessed for symptom severity in patients with MDD. We genotyped two markers in the orexin receptor genes (HCRTR1: rs2271933 and HCRTR2: rs2653349) in 619 subjects. Plasma orexin level was measured using an ELISA Kit in 132 individuals. They were divided into four subgroups according to disease status and sleep quality. We used Kruskal-Wallis test to evaluate orexin levels among subgroups. Regression models were used to test the effects of genetic variants and orexin level on sleep variables (e.g. sleep duration, efficiency, latency, and insomnia-related variables) and BDI-II while adjusted for sex and age. Results: Marker rs2271933 (HCRTR1) showed association with PSQI scores (p=0.006). Individuals carry G allele had increased risk for MDD (OR=1.48, p=0.014), and exhibited poor daytime function (OR=1.46, p=0.0124). Plasma orexin level was significantly higher (p=0.04) in the control group with good sleep quality (median: 0.67) than other subgroups (the lowest level in MDD with poor sleep quality: 0.058). Higher orexin level had protective effects on quantity (OR=0.39, p=0.014) and frequency (OR=0.36, p=0.019) of sleep latency. Longer sleep efficiency is associated with higher plasma orexin level (β=2.48, p=0.027). Meanwhile, orexin level was negatively correlated with BDI-II score (β= -4.129, p=0.016). Conclusion: Both genetic variants of orexin receptor genes and plasma orexin level show effects on sleep related features and mood disturbance. Lower plasma orexin level is associated with poor sleep quality and more severe depressive symptoms. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T10:42:08Z (GMT). No. of bitstreams: 1 ntu-102-R00849027-1.pdf: 497279 bytes, checksum: 697a66ef66a2fcb7a0d9483cbb1d6d33 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | Acknowledge-----I
Abstract (Chinese)-----III Abstract (English)-----IV Table contents-----VII Figure contents-----VIII Appendix contents-----IX Introduction-----1 Material and Methods-----7 Participants-----7 Measurements-----8 Experiments-----9 Statistical analysis-----12 Results-----14 Discussion-----17 Reference-----23 Tables-----33 Figures-----41 Appendix-----44 | |
| dc.language.iso | en | |
| dc.subject | 酵素免疫分析法 | zh_TW |
| dc.subject | 促醒激素 | zh_TW |
| dc.subject | 憂鬱症 | zh_TW |
| dc.subject | 睡眠品質 | zh_TW |
| dc.subject | 失眠 | zh_TW |
| dc.subject | 基因關聯性 | zh_TW |
| dc.subject | Enzyme-linked immunosorbent assay (ELISA) | en |
| dc.subject | Sleep quality | en |
| dc.subject | Insomnia | en |
| dc.subject | Genetic association | en |
| dc.subject | Orexin (hypocretin) | en |
| dc.subject | Major depressive disorder | en |
| dc.title | 促醒激素系統對睡眠品質與情緒障礙的影響 | zh_TW |
| dc.title | The effect of orexin system on sleep quality and mood disturbance | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳為堅,邱麗珠,蕭朱杏 | |
| dc.subject.keyword | 促醒激素,憂鬱症,睡眠品質,失眠,基因關聯性,酵素免疫分析法, | zh_TW |
| dc.subject.keyword | Orexin (hypocretin),Major depressive disorder,Sleep quality,Insomnia,Genetic association,Enzyme-linked immunosorbent assay (ELISA), | en |
| dc.relation.page | 47 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2013-08-13 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 485.62 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。